TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Type
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Increasing Incidences of Chronic Diseases across the globe
4.2.2 Rising strategic initiatives by market players
4.3 RESTRAINTS
4.3.1 Voluntary product recalls from market players
4.4 OPPORTUNITY
4.4.1 Invesmtent on research & Development (R&D) for generic medicine
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET
5.3 TRENDS IN DEVELOPMENTS OF INDIVIDUAL MARKETS (EU, USA, INDIA, CHINA, OTHER)
5.4 TRENDS IN THE DEVELOPMENT OF THERAPEUTIC AREAS
5.5 TRENDS IN MANUFACTURING SITES
5.6 TRENDS IN NEW TECHNOLOGICAL PLATFORMS FOR DRUGS
5.7 TRENDS IN IP
5.8 TRENDS IN QUALITY REQUIREMENTS
5.9 TRENDS IN REGULATORY REQUIREMENTS
6 GLOBAL GENERIC DRUGS MARKET, BY TYPE
6.1 OVERVIEW
6.2 SIMPLE GENERICS
6.3 SUPER GENERICS
7 GLOBAL GENERIC DRUGS MARKET, BY BRAND
7.1 OVERVIEW
7.2 PURE GENERIC
7.3 BRANDED GENERIC
8 GLOBAL GENERIC DRUGS MARKET, BY INDICATION
8.1 OVERVIEW
8.2 CENTRAL NERVOUS SYSTEM (CNS)
8.3 CARDIOVASCULAR
8.4 UROLOGY
8.5 ONCOLOGY
8.6 RESPIRATORY
8.7 OTHERS
9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 TOPICAL
9.4 PARENTERAL
9.5 OTHERS
10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 GLOBAL GENERIC DRUGS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 Germany
11.3.2 France
11.3.3 UK
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe
11.4 ASIA-PACIFIC
11.4.1 China
11.4.2 India
11.4.3 Japan
11.4.4 South Korea
11.4.5 Australia
11.4.6 Rest of Asia-pacific
11.5 REST OF THE WORLD
11.5.1 Middle East & Africa
11.5.2 Latin America
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS, 2022
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 product launch / Product approval
12.6.2 expansion
13 COMPANY PROFILES
13.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 productS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 LUPIN PHARMACEUTICALS, INC.
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 products OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 ENDO INTERNATIONAL PLC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 productS OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 AUROBINDO PHARMA
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 productS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 ASPEN HOLDINGS
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 productS OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 CIPLA LTD
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 NOVARTIS AG
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 productS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 FRESENIUS SE & CO. KGAA
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 productS OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 KEY STRATEGIES
13.10 VIATRIS INC.
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 productS OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 TRENDS IN REGULATORY REQUIREMENTS
TABLE 3 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR SIMPLE GENERICS, BY REGION, 2019–2032 (USD BILLION)
TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR SUPER GENERICS, BY REGION, 2019–2032 (USD BILLION)
TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR PURE GENERIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR BRANDED GENERIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019–2032 (USD BILLION)
TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019–2032 (USD BILLION)
TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019–2032 (USD BILLION)
TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2032 (USD BILLION)
TABLE 14 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019–2032 (USD BILLION)
TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)
TABLE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019–2032 (USD BILLION)
TABLE 18 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019–2032 (USD BILLION)
TABLE 19 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019–2032 (USD BILLION)
TABLE 20 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)
TABLE 21 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 22 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2032 (USD BILLION)
TABLE 23 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2032 (USD BILLION)
TABLE 24 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2032 (USD BILLION)
TABLE 25 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019–2032 (USD BILLION)
TABLE 26 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)
TABLE 27 NORTH AMERICA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 28 NORTH AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 29 NORTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 30 NORTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 31 NORTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 32 US: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 33 US: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 34 US: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 35 US: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 36 US: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 37 CANADA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 38 CANADA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 39 CANADA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 40 CANADA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 41 CANADA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 42 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)
TABLE 43 EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 44 EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 45 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 46 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 47 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 48 GERMANY: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 49 GERMANY: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 50 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 51 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 52 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 53 FRANCE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 54 FRANCE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 55 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 56 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 57 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 58 UK: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 59 UK: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 60 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 61 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 62 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 63 ITALY: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 64 ITALY: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 65 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 66 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 67 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 68 SPAIN: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 69 SPAIN: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 70 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 71 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 72 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 73 REST OF EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 74 REST OF EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 75 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 76 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 77 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 78 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)
TABLE 79 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 80 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 81 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 82 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 83 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 84 CHINA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 85 CHINA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 86 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 87 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 88 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 89 INDIA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 90 INDIA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 91 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 92 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 93 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 94 JAPAN: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 95 JAPAN: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 96 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 97 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 98 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 99 SOUTH KOREA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 100 SOUTH KOREA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 101 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 102 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 103 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 104 AUSTRALIA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 105 AUSTRALIA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 106 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 107 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 108 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 109 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 110 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 111 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 112 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 113 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 114 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2019–2032 (USD BILLION)
TABLE 115 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)
TABLE 116 REST OF THE WORLD: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 117 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 118 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 119 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 120 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)
TABLE 121 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 122 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 123 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 124 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 125 LATIN AMERICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)
TABLE 126 LATIN AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)
TABLE 127 LATIN AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)
TABLE 128 LATIN AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 129 LATIN AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 130 PUBLIC PLAYERS STOCK SUMMARY
TABLE 131 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 132 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 133 EXPANSION
TABLE 134 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 135 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 136 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
TABLE 137 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 138 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
TABLE 139 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
TABLE 140 AUROBINDO PHARMA: PRODUCT OFFERED
TABLE 141 AUROBINDO PHARMA: KEY DEVELOPMENTS
TABLE 142 ASPEN HOLDINGS: PRODUCT OFFERED
TABLE 143 CIPLA LTD.: PRODUCTS OFFERED
TABLE 144 CIPLA LTD.: KEY DEVELOPMENTS
TABLE 145 NOVARTIS AG: PRODUCTS OFFERED
TABLE 146 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 147 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
TABLE 148 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 149 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
TABLE 150 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
TABLE 151 VIATRIS INC.: PRODUCT OFFERED
TABLE 152 VIATRIS INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE
FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET
FIGURE 6 GLOBAL GENERIC DRUGS MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2022 & 2032 (USD BILLION)
FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY TYPE, 2022
FIGURE 9 GLOBAL GENERIC DRUGS MARKET, BRAND SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY BRAND, 2022
FIGURE 12 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2022
FIGURE 15 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD BILLION)
FIGURE 17 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2022
FIGURE 18 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 19 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)
FIGURE 20 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 21 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 22 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022
FIGURE 23 NORTH AMEICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 24 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 25 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 26 EUROPE MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 27 EUROPE: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 28 EUROPE: GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022
FIGURE 29 ASIA-PACIFIC MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 30 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 31 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 32 REST OF THE WORLD MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 33 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 34 REST OT THE WORLD: GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022
FIGURE 35 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022
FIGURE 36 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET
FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 39 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 41 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 CIPLA LTD.: FINANCIAL OVERVIEW
FIGURE 45 CIPLA LTD.: SWOT ANALYSIS
FIGURE 46 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 NOVARTIS AG: SWOT ANALYSIS
FIGURE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 50 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 51 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT
